MA strategy deal block push come together form
Biotech

M&A remains ‘top priority’ for pharmas in face of tariff threat

Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at least for the time being.
James Waldron Apr 25, 2025 10:41am
Vine jungle rainforest

Vyne’s psoriasis drug hit with FDA hold over testicular toxicity

Apr 25, 2025 9:25am
workers

Fierce Biotech Layoff Tracker 2025: Caribou, Mural & more

Apr 25, 2025 4:00pm
Hiker having trouble climbing mountain

ALX Oncology doubles down as lead asset fails 2 phase 2 trials

Apr 25, 2025 2:25pm
breast cancer mammogram

Study illustrates pros, cons of AI readings in 3D mammography

Apr 25, 2025 12:00pm
U turn turn around refocus pivot street sign

HHS reverses course, won’t end women’s health study contracts

Apr 25, 2025 11:48am
More News

Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders

Apr 25, 2025 8:30am

Caribou cuts 32% of staff, further purges cell therapy pipeline

Apr 24, 2025 9:55pm

Ex-FDA leader joins new initiative aiming to protect vaccine use

Apr 24, 2025 1:18pm

Boston Scientific plans to make ground despite tariff headwinds

Apr 24, 2025 12:15pm